Med's Gel Drug Delivery System (GDDS) is a novel transmucosal drug delivery
method for systemic or local delivery of drugs that heretofore could
only be delivered by injection. The GDDS is based on the discovery that
receptor mediated endocytosis is enhanced when a drug is delivered in
a viscous solution with a formulation viscosity that approximates the
intracellular viscosity of the mucosal target cells. The GDDS does not
require potentially toxic permeation enhancers or chemical modification
of the active agent to facilitate delivery.
Robert Langer, Ph.D., MIT
David Edwards, Ph.D. (while at Penn State)
Daniel Deaver, Ph.D. (while at Penn State)
drugs administered to mucous membranes are transcytosed to the abundant
capillary networks underlying them, thereby allowing the drugs to
rapidly enter the bloodstream. This delivery route avoids first pass
metabolism in the gut and liver.
GDDS offers many advantages over multiple subcutaneous or intramuscular
injections currently required to treat a variety of conditions such
as infertility, diabetes, multiple sclerosis and cancer.
Painless, non-invasive administration
Convenient delivery, no device is required
Improved patient compliance and patient outcome